BioWorld BioWorld MedTech BioWorld Asia BioWorld Science

BioWorld

Post-Pfizer dropout, Lilly Achieves GLP-1 win in phase III
Days after Pfizer Inc. pulled the plug on its oral GLP-1 candidate danuglipron, Eli Lilly and Co. aired positive top-line data from the phase III trial called Achieve-1...

More in BioWorld

BioWorld MedTech

Ouch! Tariffs hit med tech harder than expected
First quarter earnings reports from Johnson & Johnson and Abbott Laboratories provided some surprising insights into the likely hit med-tech companies will sustain with...

More in BioWorld MedTech

BioWorld Science

WHO member states outline pandemic plan
After more than three years of discussion, the World Health Organization’s Intergovernmental Negotiating Body (INB) has agreed on a proposal to prevent, prepare and respond...

More in BioWorld Science

BioWorld Asia

Hightide’s HTD-1801 meets phase III endpoints in type 2 diabetes
Hightide Therapeutics Inc.’s berberine ursodeoxycholate (HTD-1801) met primary and secondary endpoints in the Symphony 1 and Symphony 2 phase III trials in type 2 diabetes...

More in BioWorld Asia

BioWorld Insider Podcast

As biopharma investments stumble, med tech surges: This year’s med-tech investments include $2.76B via 56 transactions in January alone. BioWorld MedTech Editor Annette Boyle discusses why the sector is performing well year to date.